CommodityCoverage
9 minutes ago
Advancing next-generation mitochondrial disease therapies, Thiogenesis Therapeutics (TTI.V TTIPF) is a clinical-stage biopharmaceutical company, set to launch Phase II trials in 2025 for its lead compound, TTI-0102, a next-generation thiol-active therapeutic targeting MELAS, Leigh syndrome, and pedi